CRISPR-Engineered immune cells target advanced lung cancer
NCT ID NCT05566223
Summary
This trial aimed to test a new cell therapy for metastatic non-small cell lung cancer. It planned to use a patient's own tumor-fighting immune cells, genetically edited with CRISPR technology to remove a molecular 'brake' called CISH. The goal was to see if these supercharged cells could be safely given back to patients to better control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.